Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.

Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509. [Epub ahead of print]

PMID:
31199504
2.

Identifying optimal clinical scenarios for synchrotron microbeam radiation therapy: A treatment planning study.

Smyth LML, Day LR, Woodford K, Rogers PAW, Crosbie JC, Senthi S.

Phys Med. 2019 Apr;60:111-119. doi: 10.1016/j.ejmp.2019.03.019. Epub 2019 Mar 30.

PMID:
31000070
3.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.

PMID:
30877085
4.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
5.

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.

Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT.

Oncologist. 2019 Aug;24(8):e646-e652. doi: 10.1634/theoncologist.2018-0512. Epub 2019 Jan 2.

PMID:
30602614
6.

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.

Cronin PA, Romanoff A, Zabor EC, Stempel M, Eaton A, Smyth LM, Ho AY, Morrow M, El-Tamer M, Gemignani ML.

Ann Surg Oncol. 2018 Dec;25(13):3858-3866. doi: 10.1245/s10434-018-6767-0. Epub 2018 Oct 8.

PMID:
30298320
7.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

8.

Comparative toxicity of synchrotron and conventional radiation therapy based on total and partial body irradiation in a murine model.

Smyth LML, Donoghue JF, Ventura JA, Livingstone J, Bailey T, Day LRJ, Crosbie JC, Rogers PAW.

Sci Rep. 2018 Aug 13;8(1):12044. doi: 10.1038/s41598-018-30543-1.

9.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12.

10.

Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro.

Smyth LM, Rogers PAW, Crosbie JC, Donoghue JF.

Radiat Res. 2018 Feb;189(2):146-155. doi: 10.1667/RR4633.1.

PMID:
29364085
11.

Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro.

Smyth LM, Rogers PAW, Crosbie JC, Donoghue JF.

Radiat Res. 2017 Nov 30. doi: 10.1667/RR14633.1. [Epub ahead of print]

PMID:
29189105
12.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):360.

13.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

14.

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.

Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, Hudis CA, Dang C.

Oncologist. 2017 Feb;22(2):139-143. doi: 10.1634/theoncologist.2016-0268. Epub 2017 Feb 6.

15.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT.

Breast Cancer Res Treat. 2016 Jul;158(1):91-97. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15.

16.

The normal tissue effects of microbeam radiotherapy: What do we know, and what do we need to know to plan a human clinical trial?

Smyth LM, Senthi S, Crosbie JC, Rogers PA.

Int J Radiat Biol. 2016 Jun;92(6):302-11. doi: 10.3109/09553002.2016.1154217. Epub 2016 Mar 16. Review.

PMID:
26982077
17.

Image guidance protocol for synchrotron microbeam radiation therapy.

Pelliccia D, Poole CM, Livingstone J, Stevenson AW, Smyth LM, Rogers PA, Haüsermann D, Crosbie JC.

J Synchrotron Radiat. 2016 Mar;23(2):566-73. doi: 10.1107/S1600577515022894. Epub 2016 Jan 28.

PMID:
26917145
18.

The cardiac dose-sparing benefits of deep inspiration breath-hold in left breast irradiation: a systematic review.

Smyth LM, Knight KA, Aarons YK, Wasiak J.

J Med Radiat Sci. 2015 Mar;62(1):66-73. doi: 10.1002/jmrs.89. Epub 2015 Jan 7. Review.

19.

Storage and secretion of beta-NAD, ATP and dopamine in NGF-differentiated rat pheochromocytoma PC12 cells.

Yamboliev IA, Smyth LM, Durnin L, Dai Y, Mutafova-Yambolieva VN.

Eur J Neurosci. 2009 Sep;30(5):756-68. doi: 10.1111/j.1460-9568.2009.06869.x. Epub 2009 Aug 27.

20.

N-type and P/Q-type calcium channels regulate differentially the release of noradrenaline, ATP and beta-NAD in blood vessels.

Smyth LM, Yamboliev IA, Mutafova-Yambolieva VN.

Neuropharmacology. 2009 Feb;56(2):368-78. doi: 10.1016/j.neuropharm.2008.09.007. Epub 2008 Sep 25.

21.

Novel localization of CD38 in perivascular sympathetic nerve terminals.

Smyth LM, Breen LT, Yamboliev IA, Mutafova-Yambolieva VN.

Neuroscience. 2006;139(4):1467-77. Epub 2006 Mar 31.

PMID:
16580146
22.

Nicotinamide adenine dinucleotide is released from sympathetic nerve terminals via a botulinum neurotoxin A-mediated mechanism in canine mesenteric artery.

Smyth LM, Breen LT, Mutafova-Yambolieva VN.

Am J Physiol Heart Circ Physiol. 2006 May;290(5):H1818-25. Epub 2005 Dec 9.

23.

beta-NAD is a novel nucleotide released on stimulation of nerve terminals in human urinary bladder detrusor muscle.

Breen LT, Smyth LM, Yamboliev IA, Mutafova-Yambolieva VN.

Am J Physiol Renal Physiol. 2006 Feb;290(2):F486-95. Epub 2005 Sep 27.

24.

Release of beta-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder.

Smyth LM, Bobalova J, Mendoza MG, Lew C, Mutafova-Yambolieva VN.

J Biol Chem. 2004 Nov 19;279(47):48893-903. Epub 2004 Sep 13.

Supplemental Content

Loading ...
Support Center